arrow
A

Alberto Papi

University of Ferrara
H指数:110
被引数:4.9万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Weight Loss, FVC Decline, and Composite Physiologic Index as Complementary Prognostic Indicators in Idiopathic Pulmonary Fibrosis over the Disease Course: Time-Updated and Landmark Analysis

体重下降、FVC下降及复合生理指数作为特发性肺纤维化疾病进程中补充性预后指标:时间更新与里程碑分析

2026-11-070
PRE
Adipokines in Obese Asthma: A Complex Relationship Influenced More by Sex, Weight, and Oral Steroid Treatment Than Disease Severity

肥胖性哮喘中的脂肪因子:一种受性别、体重和口服糖皮质激素治疗影响大于疾病严重性的复杂关系

2026-04-030
OAAI
Transient Early Blood Eosinophil Increases Do Not Affect Dupilumab's Long-Term Efficacy in Patients with Moderate-to-Severe Asthma

中重度哮喘患者中,短暂的早期血液嗜酸性粒细胞增多不影响Dupilumab的长期疗效。

2025-11-140
PRE
Cluster Analysis to Identify Distinct Asthma Phenotypes in the ATLANTIS Cohort

聚类分析以识别ATLANTIS队列中不同的哮喘表型

2025-11-010
OAAI
An anti-inflammatory reliever algorithm approach to asthma management in adults: an open-label, single-arm trial

一种用于成人哮喘管理的抗炎缓解算法方法:一项开放标签、单臂试验

2025-10-210
OAAI
Assessment of the role of small airway dysfunction in relation to exacerbation risk in patients with well controlled asthma (ATLANTIS): an observational study

评估小气道功能障碍在哮喘控制良好患者中与加重风险相关的作用(ATLANTIS):一项观察性研究

2025-09-290
PRE
Type 2 inflammation biomarkers and their association with response to dupilumab in COPD (BOREAS): an analysis of a randomised, placebo-controlled, phase 3 trial

II型炎症生物标志物及其与COPD患者对度普利单抗反应的相关性(BOREAS):一项随机、安慰剂对照III期试验的分析

2025-07-090
OAAI
Dupilumab reduces acute exacerbations and improves lung function in patients with COPD with type 2 inflammation irrespective of body mass index, airflow obstruction, dyspnea, and exercise capacity index scores
2025-05-010
OA
Efficacy, safety, and immunogenicity of the AS01E-adjuvanted respiratory syncytial virus prefusion F protein vaccine (RSVPreF3 OA) in older adults over three respiratory syncytial virus seasons (AReSVi-006): a multicentre, randomised, observer-blinded, placebo-controlled, phase 3 trial

AS01E佐剂呼吸道合胞病毒前融合F蛋白疫苗(RSVPreF3 OA)在老年人群中的有效性、安全性和免疫原性研究(跨越三个呼吸道合胞病毒流行季)(AReSVi-006):一项多中心、随机、观察者设盲、安慰剂对照的III期临床试验

2025-04-140
PRE
The Bronchodilator and Anti-Inflammatory Effect of Long-Acting Muscarinic Antagonists in Asthma: An EAACI Position Paper

长效毒蕈碱拮抗剂在哮喘中的支气管扩张和抗炎作用:EAACI立场文件

2025-04-110
PRE
Effect of Dupilumab on Health-Related Quality of Life and Respiratory Symptoms in Patients With COPD and Type 2 Inflammation

Dupilumab对具有COPD和2型炎症患者的健康相关生活质量及呼吸道症状的影响

CHEST
IF8.6
2025-01-310
OAAI